Tempus Gene Library

This gene overview is brought to you as part of Tempus’ goal to inform providers about our genomic testing panels and the genes included in our offerings. Through our robust de-identified database of clinical information coupled with molecular testing results, we are capable of providing unique insights into these gene alterations. Many of the gene alterations reported on our somatic and germline panels are often key inclusion criteria for clinical trials.

mTOR Gene

Mammalian Target of Rapamycin

The mTOR gene encodes a phosphatidylinositol serine/threonine kinase protein that functions in response to DNA damage and nutrient deprivation. It is part of the mTORC1 and mTORC2 signaling complexes that regulate translation, and its function in the PI3K-AKT-mTOR signaling pathway regulates cellular proliferation and survival. Activating mutations and overexpression of mTOR are associated with cancer progression.

mTOR alterations in 10 most common cancers—Tempus database

image description
The above graph is representative of the 3.8M+ de-identified patient records in the Tempus database as of September 30, 2021.

FDA approved mTOR inhibitors

TherapyTumor type (indication)Biomarker
TORISEL® temsirolimusrenal cell carcinomanone
AFINITOR® everolimustuberous sclerosis complex (TSC)–associated renal angiomyolipomaTSC
AFINITOR® everolimusbreast cancerHR+/HER2-
AFINITOR® everolimusneuroendocrine tumorsnone
AFINITOR® everolimusrenal cell carcinomanone
As of September 30, 2021. RR – response rate; mPFS – median PFS; mOS – median Overall Survival in months; NE – not evaluated.

Select strategies in clinical development targeting mTOR signaling

MechanismPhase 2
multi-kinase inhibitorsamotolisib (LY3023414)
mTOR inhibitorsapanisertib (TAK-228) nab-rapamycin (ABI-009) AZD2014 MLN0128

View a more comprehensive list of clinical trials for patients with mTOR mutated cancers. The Tempus TIME Trial® Program brings the right clinical trials to the right patients, in days instead of months. Learn how you can enroll today.

Additional resources for mTOR gene

Additional resources on variants

Join the movement

We are committed to helping advance cancer treatment for patients. We believe that every new test is an investment in the development of patient care for the future.